HOME >> MEDICINE >> NEWS
EVEREST data on use of tolvaptan published in JAMA and featured at ACC

PRINCETON, N.J., March 25, 2007-- Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure (ADHF) in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial Efficacy of Vasopressin antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) published in the March 28 issue of the Journal of the American Medical Association (JAMA). These data were presented at the American College of Cardiology's 56th Annual Scientific Sessions (ACC).

The phase 3 EVEREST trial, involving a total of 4,133 ADHF patients, represents three studies: a long-term outcomes trial evaluating patients after their discharge for a minimum of 60 days of treatment, and two identical, embedded short-term pivotal studies that examined tolvaptan compared to placebo over seven days of inpatient care or discharge, whichever came first.

Data from the two short-term studies documented that tolvaptan treatment yielded significantly greater improvements than placebo based on the primary endpoint (study A: p less than 0.001 and study B: p less than 0.001), which was the composite score of changes in patient-assessed global clinical status and changes in body weight at day seven or discharge. Long-term tolvaptan use did not differ from placebo on either of the study's two primary endpoints: deaths from all causes (p equal to 0.68) or from the combined endpoint of cardiovascular (CV) deaths or subsequent hospitalization for worsening HF (p equal to 0.55).

"Tolvaptan exhibited short-term symptomatic benefits in patients hospitalized with worsening heart failure," said investigator Marvin A. Konstam, M.D., chief of the Division of Cardiology at the Tufts- New England
'"/>

Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Porter Novelli
27-Mar-2007


Page: 1 2 3 4 5

Related medicine news :

1. Is most published research really false?
2. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
3. In stroke, negative studies less likely to get published
4. Landmark study on diabetic foot infection published
5. New international standards for tuberculosis care published
6. Research published in the NEJM challenges 30-year-old standard of care for lupus patients
7. Newly published summer camp health guideline advises parents, camp directors
8. Child sex abuse policy recommendations published in Science magazine
9. Aqueous Humor Outflow featured in Investigative Ophthalmology & Visual Science
10. Health effects of functional foods featured during four-day symposium, Sept. 10-13
11. Rare, historic medical cartoons to be featured in film series

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EVEREST data use tolvaptan published JAMA and featured ACC

(Date:9/4/2015)... ... 2015 , ... According to an article published September 1 by ... homes and assisted living facilities are receiving insufficient care that could actually be shortening ... was at one point close to death, not because of a medical condition, but ...
(Date:9/4/2015)... ... 04, 2015 , ... According to an article published August 18th ... to an impact force that is great enough to cause a traumatic brain injury. ... equipment so that coaches or officials would instantly see if a player may have ...
(Date:9/4/2015)... CA (PRWEB) , ... September 04, 2015 , ... According ... in the Journal of the American Dental Association presented data showing that it is ... comparing a group of pregnant women that had undergone local anesthesia with a group ...
(Date:9/4/2015)... ... September 04, 2015 , ... On the ... effectively doubled the size of its annual health tech innovation program. Now featuring ... health startups to compete for cash and prizes to advance their technologies toward ...
(Date:9/4/2015)... ... ... With TransCel from Pixel Film Studios users can simulate celluloid media transitions ... users have full control over camera position and angle within 3D space from start ... text, and more. With TransCel the possibilities are endless. , Users have full control ...
Breaking Medicine News(10 mins):Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2
(Date:9/4/2015)... 2015 Physician E-sampling is becoming well established ... a key marketing sales tactic in recent years. However, ... as a supplement to traditional sampling. ... physician E-sampling has been seeded across multiple therapeutic areas- ... E-sampling has been in place for five or more ...
(Date:9/4/2015)... -- Janssen Research & Development, LLC (Janssen) announced today ... accepted for Priority Review the Biologics License Application ... with multiple myeloma who are refractory to both ... (IMiD), or who have received three or more ... an IMiD. This is referred to as "double ...
(Date:9/4/2015)... Fair Rate Funding, a lawsuit funding firm located in ... in lawsuit filings in connection with the blood thinning drug, ... Philadelphia Court of Common Pleas has risen ... Louisiana multi---district litigation (MDL), located in the ... Louisiana , the filings are also on the rise, ...
Breaking Medicine Technology:Current and Future Trends in Physician E-Sampling Programs for the Pharmaceutical Industry 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3
Cached News: